Journal
VIRUSES-BASEL
Volume 11, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/v11070610
Keywords
hantavirus; hemorrhagic fever with renal syndrome; hantavirus pulmonary syndrome; vaccine; antiviral
Categories
Funding
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R01AI32313]
Ask authors/readers for more resources
Hantaviruses, members of the order Bunyavirales, family Hantaviridae, have a world-wide distribution and are responsible for greater than 150,000 cases of disease per year. The spectrum of disease associated with hantavirus infection include hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) also known as hantavirus cardiopulmonary syndrome (HCPS). There are currently no FDA-approved vaccines or treatments for these hantavirus diseases. This review provides a summary of the status of vaccine and antiviral treatment efforts including those tested in animal models or human clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available